CTMX CytomX Therapeutics Inc.

11.79
-0.03  -0%
Previous Close 11.82
Open 11.93
Price To Book 4.35
Market Cap 534,222,161
Shares 45,311,464
Volume 241,642
Short Ratio
Av. Daily Volume 390,241

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data at ASCO June 1, 2019. 4/65 partial responses.
CX-072 - PROCLAIM-CX-072
Solid tumors
Phase 1/2 preliminary data due 2019.
BMS-986249 and nivolumab
Solid Tumors or Lymphomas
Phase 1/2 updated data at AACR April 2, 2019. 7/71 partial responses.
CX-2009 - PROCLAIM
Solid tumors

Latest News

  1. Analyst: CytomX Therapeutics Validated By AbbVie Decision
  2. CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
  3. Did You Manage To Avoid CytomX Therapeutics's (NASDAQ:CTMX) Painful 51% Share Price Drop?
  4. Here’s What Hedge Funds Think About CytomX Therapeutics, Inc. (CTMX)
  5. CytomX Therapeutics Provides Update on Anti-PD-L1 Probody CX-072 at 2019 ASCO Annual Meeting
  6. CytomX Therapeutics to Present at Upcoming Healthcare Conferences
  7. Edited Transcript of CTMX earnings conference call or presentation 9-May-19 9:00pm GMT
  8. CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting
  9. CytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript
  10. Were Hedge Funds Right About Dumping CytomX Therapeutics, Inc. (CTMX)?
  11. CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
  12. CytomX Therapeutics: 1Q Earnings Snapshot
  13. CytomX Therapeutics Announces First Quarter 2019 Financial Results
  14. Edited Transcript of CTMX earnings conference call or presentation 6-Nov-18 10:00pm GMT
  15. CytomX Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
  16. CytomX Therapeutics to Announce First Quarter 2019 Financial Results
  17. Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for
  18. Long-Term "GameChangers" in Biotech
  19. CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to Board of Directors
  20. What Kind Of Investor Owns Most Of CytomX Therapeutics, Inc. (NASDAQ:CTMX)?